M
Michael S. Gordon
Researcher at Pinnacle Financial Partners
Publications - 172
Citations - 13887
Michael S. Gordon is an academic researcher from Pinnacle Financial Partners. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 43, co-authored 153 publications receiving 12207 citations. Previous affiliations of Michael S. Gordon include GlaxoSmithKline & Indiana University – Purdue University Indianapolis.
Papers
More filters
Journal ArticleDOI
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Patrick Schöffski,Michael S. Gordon,David Smith,Razelle Kurzrock,Adil Daud,Nicholas J. Vogelzang,Yihua Lee,Christian Scheffold,Geoffrey I. Shapiro +8 more
TL;DR: Clinical antitumour activity of cabozantinib was observed in a subset of tumour types: CRPC and OC were evaluated further in expansion cohorts and Interpretation of efficacy outcomes was limited by early termination of the randomised portion of the trial.
Journal ArticleDOI
An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
Michael S. Gordon,Francisco Robert,Daniela Matei,David S. Mendelson,Jonathan W. Goldman,E. Gabriela Chiorean,Robert Matthew Strother,Ben K. Seon,William D. Figg,Cody J. Peer,Delia Alvarez,Bonne J. Adams,Charles P. Theuer,Lee S. Rosen +13 more
TL;DR: TRC105 was well tolerated with bevacizumab and clinical activity was observed in a VEGF inhibitor–refractory population of patients and several patients who had previously progressed on bevacsumab or V EGF receptor tyrosine kinase inhibitor treatment experienced reductions in tumor volume.
Journal ArticleDOI
The in vitro and in vivo effects of stem cell factor on human hematopoiesis.
Ronald Hoffman,Jie Tong,John E. Brandt,C. M. Traycoff,E Bruno,Edward F. Srour,Michael S. Gordon,Brian W. Mcguire,Ian K. McNiece +8 more
TL;DR: In vivo administration of SCF led to an increase in both differentiated and primitive hematopoietic progenitor cells within the marrow, suggesting that in vivo SCF administration may be useful for improving the quality of bone marrow grafts to be used either for autologous or allogeneic bone marrow transplantation.
Journal ArticleDOI
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer
Johanna C. Bendell,Michael S. Gordon,Herbert Hurwitz,Suzanne F. Jones,David S. Mendelson,Gerard C. Blobe,Neeraj Agarwal,Carolyn H. Condon,Dawn Wilson,Amelia E. Pearsall,Yijun Yang,Ty McClure,Kenneth M. Attie,Matthew L. Sherman,Sunil Sharma +14 more
TL;DR: Dalantercept was well-tolerated at doses up to 1.6 mg/kg, with a safety profile distinct from inhibitors of the VEGF pathway, and displayed promising antitumor activity in patients with advanced refractory cancer, and multiple phase II studies are underway.
Journal ArticleDOI
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
Adil Daud,Harriet M. Kluger,Razelle Kurzrock,Frauke Schimmoller,Aaron Weitzman,Thomas A. Samuel,Ali H. Moussa,Michael S. Gordon,Geoffrey I. Shapiro +8 more
TL;DR: Cabozantinib has clinical activity in patients with metastatic melanoma, including uveal melanoma and reduction in target lesions from baseline was seen in 55% of evaluable patients overall and in 59% ofevaluable patients with uveale melanoma.